Table 1 from Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2-Deficient Meningiomas
Abstract
The relative response of AG-NF2-Luc2 tumor xenografts in mice prior to and after treatment with vehicle, brigatinib, INK128, or brigatinib + INK128.
Fields of Study & Subjects
Meningioma and schwannoma management
Neurofibromatosis and Schwannoma Cases
PI3K/AKT/mTOR signaling in cancer
Publication details
- Publication date
- 27 January 2026